<DOC>
	<DOCNO>NCT01822548</DOCNO>
	<brief_summary>The purpose study evaluate effect DPP-IV inhibitor Vildagliptin vs. Glibenclamide circulate endothelial progenitor cell ( EPCs ) number type 2 diabetes patient metformin failure . Subjects follow 12 month randomization .</brief_summary>
	<brief_title>Effect Vildagliptin vs. Glibenclamide Circulating Endothelial Progenitor Cell Number Type 2 Diabetes</brief_title>
	<detailed_description>Diabetic patient show high cardiovascular risk compare non-diabetic patient . It therefore crucial blood glucose lower drug reveal favorable cardiovascular risk profile independently metabolic control . EPCs subset circulate mononuclear cell derive bone marrow . EPCs play fundamental role formation new blood vessel ( neo-endothelization ) repair exist blood vessel ( re-endothelization ) order maintain endothelial homeostasis integrity . Endothelial damage tissue ischemia , release growth factor cytokine , represent strong stimulus mobilization EPCs bone marrow . Reduced EPC number relate presence traditional risk factor cardiovascular disease development atherosclerosis show predict cardiovascular ( CV ) risk . Type 2 diabetes know associate increased CV risk reduce EPC number . Recent data suggest DDP-IV inhibitor might involve mechanism promote bone-marrow EPC mobilization . This putative ancillary effect DPP-IV might favorable impact type 2 diabetes , condition characterize increase CV risk . This randomized , open-label , active-treatment-controlled , two parallel arm ( 2:1 ) , intervention trial compare DPP-IV inhibitor Vildagliptin ( 100 mg daily ) Glibenclamide ( maximum daily dose 10 mg ) . Treatment allocation titration regimens blind . Primary end-point : Absolute relative change EPC number visit : V0 ( randomization ) , V2 ( month 4 ) , V3 ( month 8 ) V4 ( month 12 ) . Secondary end-point : Absolute relative change HbA1C compare baseline .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Age equal 35 year ; Diagnosis type 2 diabetes mellitus define American Diabetes Association , least one year disease duration time screen visit ; Blood glucose lower treatment Metformin alone ( monotherapy ) stable dose least 1.5 g/day ( maximum tolerate dose ) 3 month prior screen visit ; Insufficient metabolic control define recent ( last six month ) HbA1c ≥ 7 % peripheral laboratory confirm time screening ; Absence recent clinicallyrelevant progression micro macrovascular complication ( see exclusion criterion ) ; Written inform consent participate study . Exclusion criterion : Age 35 year Type 1 diabetes cause diabetes ( pancreatectomy , gestational diabetes , etc . ) HbA1c &lt; 7 % ≥ 9 % screen visit Treatment blood glucose lower treatment Metformin six month screen visit BMI &lt; 20 ≥ 40 kg/m2 , current/ past history clinicallyrelevant eat disorder ( include limit nervous anorexia , bulimia , bingeeating disorder , etc . ) Significant progression diabetic macroangiopathy cardiovascular disease six month prior study visit Significant progression diabetic microangiopathy six month prior study visit Organ failure severe disease limit life expectancy ; Beginning , three month screen visit , kind drug modify glycemic level ( betablockers , diuretics… ) , acute disease ( acute infection , urinary tract infection… ) three month screen visit History inflammatory/infective/autoimmune chronic disease History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , gastric surgery , inflammatory bowel disease ; Any clinically significant abnormality identify physical examination , laboratory test , ECG vital sign screen judgment investigator would preclude safe completion study ; Uncontrolled inadequately control hypertension screening ( SBP &gt; 190 DBP &gt; 100 mmHg ) Ongoing pregnancy absence effective contraception woman childbearing potential Contraindications maintenance background therapy ( Metformin ) , include limited chronic kidney failure plasma creatinine concentration &gt; 1.5 mg/dL , severe respiratory failure , etc . ; Contraindications use Sulfonylurea ; Contraindications use DPPIV Inhibitor ; Laboratory finding , disease condition , screen visit might interfere study measurement : 1 . Hemoglobinopathy known affect HbA1c assay ; 2 . Known chronic liver disease , include HBV HCV infection ; 3 . Liver maker ( AST , ALT , ALP , GGT , bilirubin ) 2 time upper normal limit ; 4 . Amylase and/or lipase 2 time upper normal limit ; Chronic use systemic and/or inhale corticosteroid ( topical corticosteroid allow ) ; History low compliance , clinicallyrelevant psychiatric disorder current/ historical finding suggest patient inappropriate follow study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>EPC</keyword>
	<keyword>diabetes</keyword>
	<keyword>DPP IV inhibitor</keyword>
</DOC>